Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report

Transplantation Proceedings

Volumn 44, Issue 10, 2012, Pages 3037-3040

  Xie, L ^a   Nester, C M ^a   Reed, A I ^a   Zhang, Y ^a,b   Smith, R J ^a,b   Thomas, C P ^a,c,d  

^a Department of Internal Medicine ^*  (United States)

^b Genetics Program   (United States)

^c Molecular and Cellular Biology Program   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; CORTICOSTEROID; CREATININE; DISINTEGRIN; ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE; METALLOPROTEINASE; THROMBOSPONDIN 1; VALGANCICLOVIR;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; CASE REPORT; COMPLEMENT BLOOD LEVEL; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PERIOPERATIVE PERIOD; PLASMAPHERESIS; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINALYSIS; VIREMIA;

ACUTE KIDNEY INJURY; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT FACTOR H; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MUTATION; PLASMAPHERESIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870161966     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.07.141     Document Type: Article

References (33)

1. M. Noris, G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med 361 2009 1676
2. C. Loirat, V. Frémeaux-Bacchi Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 2011 60
3. D. Kavanagh, A. Richards, Atkinson Complement regulatory genes and hemolytic uremic syndromes J Annu Rev Med 59 2008 293
4. I. Moore, L. Strain, I. Pappworth Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome Blood 115 2010 379
5. C. Skerka, P.F. Zipfel, M.A. Dragon-Durey Autoantibodies in haemolytic uraemic syndrome (HUS) Thrombosis and Haemostasis 101 2009 227
6. T.K. Maga, C.J. Nishimura, A.E. Weaver Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome Hum Mutat 31 2010 E1445
7. K.M. Zareba Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria Drugs Today 43 2007 539
8. C. Loirat, S. Babu, R. Furman Eculizumab efficacy and safety in patients with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange/infusion [poster] Presented at the 16th Congress of European Hematology Association (EHA). London, UK 2011
9. C. Loirat, P. Muus, C. Legendre A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome receiving chronic plasma exchange/infusion [poster] Presented at the 16th Congress of European Hematology Association (EHA). London, UK 2011
10. J. Nürnberger, T. Philipp, O. Witzke Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 2009 542
11. J.C. Davin, V. Gracchi, A. Bouts Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation Am J Kidney Dis 55 2010 708
12. S.I. Al-Akash, P.S. Almond, V.H. Savell Jr Eculizumab induces long-term remission in recurrent posttransplant HUS associated with C3 gene mutation Pediatr Nephrol 26 2011 613
13. C. Nester, Z. Stewart, D. Myers Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 6 2011 1488
14. M. Weitz, O. Amon, D. Bassler Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome Pediatr Nephrol 26 2011 1325
15. L.B. Zimmerhackl, J. Hofer, G. Cortina Prophylactic eculizumab after renal transplant in atypical hemolytic-uremic syndrome N Engl J Med 362 2010 1746
16. D. Kavanagh, A. Richards, T. Goodship Transplantation in atypical hemolytic uremic syndrome Semin Thromb Hemost 36 2010 653
17. J.M. Saland, S.H. Emre, B.L. Shneider Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation Am J Transplant 6 2006 1948
18. E. Bresin, E. Daina, M. Nori Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background International Registry of Recurrent and Familial HUS/TTP Clin J Am Soc Nephrol 1 2006 88
19. C. Loirat, V. Fremeaux-Bacchi Hemolytic uremic syndrome recurrence after renal transplantation Pediatr Transplant 12 2008 619
20. G. Remuzzi, P. Ruggenenti, D. Codazzi Combined kidney and liver transplantation for familial haemolytic uraemic syndrome Lancet 359 2002 1671
21. G. Remuzzi, P. Ruggenenti, M. Colledan Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation Am J Transplant 5 2005 1146
22. J.M. Saland, P. Ruggenenti, G. Remuzzi Liver-kidney transplantation to cure atypical hemolytic uremic syndrome J Am Soc Nephrol 20 2009 940
23. Y. Zhang, N.C. Meyer, K. Wang Causes of alternative pathway dysregulation in dense deposit disease Clin J Am Soc Nephrol 7 2012 265
24. J. Caprioli, M. Noris, S. Brioschi International Registry of Recurrent and Familial HUS/TTP Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood 108 2006 1267
25. C. Loirat, M. Noris, V. Fremeaux-Bacchi Complement and the atypical hemolytic uremic syndrome in children Pediatr Nephrol 23 2008 1957
26. C. Licht, A. Weyersberg, S. Heinen Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15 Am J Kidney Dis 45 2005 415
27. J.M. Saland, P. Ruggenenti, G. Remuzzi Consensus Study Group Liver-kidney transplantation to cure atypical hemolytic uremic syndrome J Am Soc Nephrol 20 2009 940
28. A.R. Koskinen, E. Tukiainen, J. Arola Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome Am J Transplant 11 2011 1885
29. A. Hill, R.P. Rother, L. Arnold Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization Haematologica 95 2010 567
30. A. Röth, C. Hock, A. Konik Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena Int J Hematol 93 2011 704
31. A.M. Risitano, R. Notaro, L. Marando Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab Blood 113 2009 4094
32. C.J. Mache, B. Acham-Roschitz, V. Frémeaux-Bacchi Complement inhibitor eculizumab in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 4 2009 1312
33. V. Chatelet, V. Frémeaux-Bacchi, T. Lobbedez Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome Am J Transplant 9 2009 2644